<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00880581</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-14820</org_study_id>
    <secondary_id>SU-03272009-2038</secondary_id>
    <secondary_id>LYMNHL0064</secondary_id>
    <nct_id>NCT00880581</nct_id>
  </id_info>
  <brief_title>A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas</brief_title>
  <official_title>A Phase 2 Study of Intratumoral Injection PF-3512676 in Combination With Local Radiation in Low-Grade B-Cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ronald Levy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the feasibility of using intra-tumoral PF-3512676 in combination with local
      radiation as a therapy for lowgrade b-cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall ObjectiveResponse (ORR) Rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Overall objective response rate (OOR) at time of best response was assessed as the sum of the Complete Response (CR) rate and the Partial Response (CR, PR) rate. Response was assessed per the Cheson Criteria, as below.
Complete Response (CR) = Complete disappearance of all lesions, evidence, and effects of disease
CR/unconfirmed (CRu) = residual lymph node mass &gt;1.5 cm but regressed &gt;75%, with 1 residual lymph node mass &gt;1.5 cm that has regressed by &gt;75% and/or increased number or size of bone marrow aggregates without cytologic or architectural atypia
Partial Response (PR) = ≥50% decrease in SPD of the 6 largest lesions with no increase in the size of the other nodes; splenic / hepatic nodules regress ≥50%, and with no new sites of disease Stable disease (SD) = less than PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate After Cycle 2</measure>
    <time_frame>6 months</time_frame>
    <description>Response after a second cycle of treatment was assessed per the Cheson Criteria, as below.
Complete Response (CR) = Complete disappearance of all lesions, evidence, and effects of disease
CR/unconfirmed (CRu) = residual lymph node mass &gt;1.5 cm but regressed &gt;75%, with 1 residual lymph node mass &gt;1.5 cm that has regressed by &gt;75% and/or increased number or size of bone marrow aggregates without cytologic or architectural atypia
Partial Response (PR) = ≥50% decrease in SPD of the 6 largest lesions with no increase in the size of the other nodes; splenic / hepatic nodules regress ≥50%, and with no new sites of disease Stable disease (SD) = less than PR.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell</condition>
  <condition>Lymphomas: Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>PF-3512676</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with 18 mg PF-3512676 by intratumoral injection on day 2 following local radiotherapy, then weekly for a total of 10 injections over 10 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-3512676</intervention_name>
    <description>18 mg injection</description>
    <arm_group_label>PF-3512676</arm_group_label>
    <other_name>CpG 7909</other_name>
    <other_name>CpG</other_name>
    <other_name>ProMune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Local radiotherapy</intervention_name>
    <description>2 gray (2 Gy) on each of Days 1 and 2</description>
    <arm_group_label>PF-3512676</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy confirmed low-grade B-cell lymphoma diagnosed as follicular grade 1 or 2,
             marginal zone or small lymphocytic lymphoma of any initial stage.

          -  Patients may be either treatment-naïve; relapsed from; or refractory to prior therapy.
             (15 treatment-naïve and 15 relapsed/refractory patients will be enrolled)

          -  Patients must have at least one site of disease that is accessible for intratumoral
             injection of PF-3512676 percutaneously

          -  Tumor specimens must be available for immunological studies either from a previous
             biopsy or a new biopsy obtained before the initiation of the study.

          -  Patients must have measurable disease other than the injection site or biopsy site.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≥ 1

          -  Karnofsky Performance Status (KPS) of ≥ 70

          -  ≥ 18 years of age

          -  White blood cells (WBC) ≥ 2,000/uL

          -  Platelet count ≥ 75,000/mm³

          -  Absolute neutrophil count (ANC) ≥ 1000

          -  Serum creatinine ≤ 2.0 mg/dL.

          -  Bilirubin ≤ 1.5 mg/dL

          -  Serum glutamic oxalocetic transaminase (SGOT) / serum glutamic pyruvic transaminase
             (SGPT) ratio &lt; 3 x upper limit of normal (ULN)

          -  Required wash out periods for prior therapy:

               -  Topical therapy: 2 weeks

               -  Chemotherapy: 4 weeks

               -  Radiotherapy: 4 weeks

               -  Other investigational therapy: 4 weeks

               -  Rituximab: 12 weeks

          -  Patients of reproductive potential and their partners must agree to use an effective
             (&gt;90% reliability) form of contraception during the study and for 4 weeks following
             the last study drug administration.

          -  Women of reproductive potential must have a negative urine pregnancy test.

          -  Life expectancy &gt; 4 months.

          -  Able to comply with the treatment schedule.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Pre-existing autoimmune or antibody mediated disease including:

               -  Systemic lupus, erythematosus

               -  Rheumatoid arthritis

               -  Multiple sclerosis

               -  Sjogren's syndrome

               -  Autoimmune thrombocytopenia, but excluding controlled thyroid disease

               -  Presence of autoantibodies without clinical autoimmune disease.

          -  Known history of human immunodeficiency virus (HIV).

          -  Patients with active infection or with a fever &gt; 38.5 C within 3 days prior to the
             first scheduled treatment.

          -  Central nervous system (CNS) metastases

          -  Prior malignancy (active within 5 years of screening) except basal cell or completely
             excised non-invasive squamous cell carcinoma of the skin, or in situ squamous cell
             carcinoma of the cervix.

          -  History of allergic reactions attributed to compounds of similar composition to
             PF-3512676

          -  Current anticoagulant therapy [aspirin (ASA) ≤ 325 mg per day allowed]

          -  Significant cardiovascular disease [ie, New York Heart Association (NYHA) class 3
             congestive heart failure; myocardial infarction with the past 6 months; unstable
             angina; coronary angioplasty with the past 6 months; uncontrolled atrial or
             ventricular cardiac arrhythmias].

          -  Pregnant or lactating.

          -  Any other medical history, including laboratory results, deemed by the investigator to
             be likely to interfere with their participation in the study, or to interfere with the
             interpretation of the results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Levy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999 Apr;17(4):1244. Review. Erratum in: J Clin Oncol 2000 Jun;18(11):2351.</citation>
    <PMID>10561185</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2009</study_first_submitted>
  <study_first_submitted_qc>April 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2009</study_first_posted>
  <results_first_submitted>April 23, 2016</results_first_submitted>
  <results_first_submitted_qc>January 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 14, 2017</results_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Ronald Levy</investigator_full_name>
    <investigator_title>Robert K. and Helen K. Summy Professor in the School of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PF-3512676</title>
          <description>To assess the feasibility of using intra-tumoral PF-3512676 (CpG 7909 or ProMune) at 18 mg per week over 10 weeks in combination with local radiation [2 gray (2Gy) on each of Days 1 and 2] as a therapy for low-grade B-cell lymphoma.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Cycle 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Cycle 2 Re-treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24">6 subjects with progessive disease were not treated and evaluated in Cycle 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PF-3512676</title>
          <description>To assess the feasibility of using intra-tumoral PF-3512676 in combination with local radiation as a therapy for lowgrade b-cell lymphoma.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall ObjectiveResponse (ORR) Rate</title>
        <description>Overall objective response rate (OOR) at time of best response was assessed as the sum of the Complete Response (CR) rate and the Partial Response (CR, PR) rate. Response was assessed per the Cheson Criteria, as below.
Complete Response (CR) = Complete disappearance of all lesions, evidence, and effects of disease
CR/unconfirmed (CRu) = residual lymph node mass &gt;1.5 cm but regressed &gt;75%, with 1 residual lymph node mass &gt;1.5 cm that has regressed by &gt;75% and/or increased number or size of bone marrow aggregates without cytologic or architectural atypia
Partial Response (PR) = ≥50% decrease in SPD of the 6 largest lesions with no increase in the size of the other nodes; splenic / hepatic nodules regress ≥50%, and with no new sites of disease Stable disease (SD) = less than PR.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PF-3512676</title>
            <description>Patients will be treated with 18 mg PF-3512676 by intratumoral injection on day 2 following local radiotherapy, then weekly for a total of 10 injections over 10 weeks.
PF-3512676: 18 mg injection
Local radiotherapy: 2 x 2 Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Overall ObjectiveResponse (ORR) Rate</title>
          <description>Overall objective response rate (OOR) at time of best response was assessed as the sum of the Complete Response (CR) rate and the Partial Response (CR, PR) rate. Response was assessed per the Cheson Criteria, as below.
Complete Response (CR) = Complete disappearance of all lesions, evidence, and effects of disease
CR/unconfirmed (CRu) = residual lymph node mass &gt;1.5 cm but regressed &gt;75%, with 1 residual lymph node mass &gt;1.5 cm that has regressed by &gt;75% and/or increased number or size of bone marrow aggregates without cytologic or architectural atypia
Partial Response (PR) = ≥50% decrease in SPD of the 6 largest lesions with no increase in the size of the other nodes; splenic / hepatic nodules regress ≥50%, and with no new sites of disease Stable disease (SD) = less than PR.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate After Cycle 2</title>
        <description>Response after a second cycle of treatment was assessed per the Cheson Criteria, as below.
Complete Response (CR) = Complete disappearance of all lesions, evidence, and effects of disease
CR/unconfirmed (CRu) = residual lymph node mass &gt;1.5 cm but regressed &gt;75%, with 1 residual lymph node mass &gt;1.5 cm that has regressed by &gt;75% and/or increased number or size of bone marrow aggregates without cytologic or architectural atypia
Partial Response (PR) = ≥50% decrease in SPD of the 6 largest lesions with no increase in the size of the other nodes; splenic / hepatic nodules regress ≥50%, and with no new sites of disease Stable disease (SD) = less than PR.</description>
        <time_frame>6 months</time_frame>
        <population>Participants with progressive disease (PD) were not re-evaluated.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-3512676</title>
            <description>Patients will be treated with 18 mg PF-3512676 by intratumoral injection on day 2 following local radiotherapy, then weekly for a total of 10 injections over 10 weeks.
PF-3512676: 18 mg injection
Local radiotherapy: 2 x 2 Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate After Cycle 2</title>
          <description>Response after a second cycle of treatment was assessed per the Cheson Criteria, as below.
Complete Response (CR) = Complete disappearance of all lesions, evidence, and effects of disease
CR/unconfirmed (CRu) = residual lymph node mass &gt;1.5 cm but regressed &gt;75%, with 1 residual lymph node mass &gt;1.5 cm that has regressed by &gt;75% and/or increased number or size of bone marrow aggregates without cytologic or architectural atypia
Partial Response (PR) = ≥50% decrease in SPD of the 6 largest lesions with no increase in the size of the other nodes; splenic / hepatic nodules regress ≥50%, and with no new sites of disease Stable disease (SD) = less than PR.</description>
          <population>Participants with progressive disease (PD) were not re-evaluated.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PF-3512676</title>
          <description>Patients will be treated with 18 mg PF-3512676 by intratumoral injection on day 2 following local radiotherapy, then weekly for a total of 10 injections over 10 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>erythema</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronald Levy</name_or_title>
      <organization>Stanford University</organization>
      <phone>6507256452</phone>
      <email>levy@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

